Abstract: Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone with remarkably enhanced in vitro activity against a wide variety of clinically relevant pathogens, especially gram-positive bacteria, including multidrug-resistant Streptococcus pneumoniae and methicillinresistant Staphylococcus aureus. It has a low propensity for selecting resistant pathogens than fluoroquinolones, since bacteria become resistant to nemonoxacin only when three different mutations occur in their quinolone resistance-determining regions. Nemonoxacin shows greater efficacy than most of the widely used fluoroquinolones in the murine model of systemic, pulmonary, or ascending urinary tract infection. Nemonoxacin has a sound PK profile in healthy volunteers. It rapidly reaches maximum concentration C max 1-2 hours after oral administration in the fasting state and has a relatively long elimination half-life of more than 10 hours, which is similar to fluoroquinolones. Approximately 60%-75% of the administered dose is excreted in unchanged form via kidneys over 24-72 hours. Phase II and III studies of oral nemonoxacin and Phase II studies of intravenous nemonoxacin have been completed in patients with community-acquired pneumonia (CAP), before which the Phase I studies of oral and intravenous nemonoxacin indicated sound tolerance and safety with healthy volunteers. The published results demonstrate that an oral dose of either 500 mg or 750 mg nemonoxacin once daily for 7 days is as effective and safe as levofloxacin 500 mg once daily for 7 days. Nemonoxacin is well-tolerated in patients with CAP. The most common adverse events of oral administration are observed in the gastrointestinal and nervous system, the incidence of which is similar to levofloxacin treatment. The Phase III studies of intravenous nemonoxacin for treating CAP and oral nemonoxacin for diabetic foot infection has been registered with promising outcomes to be expected.
Introduction
The problem of fluoroquinolone resistance, both among gram-positive cocci and gram-negative bacilli, has brought great challenge into clinical practice. 1 Therefore, the development of newer quinolone compounds with greater activity and less resistance is urgently required. Up to now, TaiGen Biotechnology has completed the multidose, dose-escalation Phase IB trials in healthy volunteers and Phase II studies of oral and intravenous nemonoxacin in Chinese patients with community-acquired pneumonia (CAP). A Phase III study of intravenous nemonoxacin for treating CAP and oral nemonoxacin for diabetic foot infection have been registered.
Here, we present a comprehensive picture of nemonoxacin under clinical development by reviewing the data available on the pharmacodynamics (PD), the pharmacokinetics (PK), and the clinical treatment studies of the antimicrobial agent.
PD in vitro activity of nemonoxacin
Based on the data reported in the previous in vitro susceptibility testing (three studies that included 2,683 strains of gram-positive cocci and 1,303 gram-negative bacilli), nemonoxacin showed potent broad-spectrum activities against most gram-positive cocci and gram-negative bacilli (Table 1) . Especially, nemonoxacin demonstrated better activity than the fluoroquinolone comparators against some typical antibiotic-resistant gram-positive organisms, like penicillin-resistant Streptococcus pneumoniae (PRSP) and fluoroquinolone-resistant S. pneumoniae. [4] [5] [6] Nemonoxacin also displayed good in vitro activities against atypical pathogens, such as Chlamydia trachomatis and C. pneumoniae. In a Canadian report, the activity of nemonoxacin against S. pneumoniae was superior to the fluoroquinolones tested, including penicillin-resistant S. pneumoniae. 4 In another study, Chen et al 5 found that among the 150 S. pneumoniae isolates, nemonoxacin had comparable activity (minimum inhibitory concentration [MIC] 90 0.06 mg/L) as gemifloxacin and much greater activity than that of levofloxacin (MIC 90 2 mg/L) and moxifloxacin. Moreover, for levofloxacin nonsusceptible (MIC $4 mg/L) S. pneumoniae isolates, nemonoxacin successfully inhibited 76.7% (23/30) of the isolates at concentration of #0.5 mg/L, while moxifloxacin inhibited 6.7% and gemifloxacin 90% at the same concentration.
Lauderdale et al 6 reported lower nemonoxacin MIC 90 (2 mg/L) among levofloxacin-resistant S. pneumoniae isolates (MIC $8 mg/L) in contrast to moxifloxacin (8 mg/L), comparable to ceftriaxone (2 mg/L), but higher than linezolid (1 mg/L), tigecycline (0.06 mg/L), and vancomycin (0.5 mg/L).
As one of the common pathogens of CAP, Haemophilus influenzae was relatively more susceptible to nemonoxacin than fluoroquinolones, evidenced by MIC 90 (4 mg/L) at least 2-fold lower than ciprofloxacin (16 mg/L), levofloxacin (8 mg/L), and moxifloxacin (.8 mg/L) ( Table 1) . 6 As for atypical pathogens, the in vitro activity of nemonoxacin (MIC 90 0.06 mg/L) against C. trachomatis was 2-to 4-fold more active than levofloxacin (MIC 90 0.25 mg/L) and doxycycline (MIC 90 0.125 mg/L), but 4-fold less active than azithromycin (MIC 90 0.015 mg/L). For C. pneumoniae, the activity of nemonoxacin (MIC 90 0.06 mg/L) was comparable to doxycycline (MIC 90 0.125 mg/L) and azithromycin (MIC 90 0.06 mg/L), but much better than levofloxacin (MIC 90 0.5 mg/L) ( Table 1) . 7 Unfortunately, the data about the in vitro activity of nemonoxacin against Mycoplasma and Legionella pneumophila are lacking.
Nemonoxacin showed greater activity than fluoroquinolone comparators against the methicillin-susceptible Staphylococcus aureus (MSSA) strains. 4 Its in vitro activity is slightly greater than fluoroquinolones against the methicillin-resistant Staphylococcus aureus (MRSA) ( Table 1 ). Nemonoxacin remained highly active against community-acquired (CA)-MRSA, while relatively higher nemonoxacin MICs ($4 mg/L) were noted among the hospital-acquired MRSA (78%; 77/99). 4 According to the researches from Taiwan, nemonoxacin demonstrated activity superior to levofloxacin against CA-MRSA isolates, but similar to moxifloxacin and gemifloxacin. 5 Nemonoxacin had slightly lower MIC 90 (1 mg/L) for CA-MRSA than ceftobiprole, vancomycin, teicoplanin, and linezolid (2 mg/L, respectively), but higher than daptomycin Nemonoxacin had stronger inhibitory activity against both methicillin-susceptible S. epidermidis (MSSE) and methicillin-resistant S. epidermidis (MRSE) than ciprofloxacin, levofloxacin, and moxifloxacin. 4, 6 The MIC 90 values of nemonoxacin against MSSE and MRSE were much lower than those of the fluoroquinolones. 4 Similarly, Lauderdale et al (Table 1) . Nemonoxacin also displayed greater activity than the fluoroquinolone comparators against E. faecalis. [4] [5] [6] In the testing of 31 strains of E. faecalis, nemonoxacin MIC 90 value was at least 2-fold lower than that of ciprofloxacin, levofloxacin, and moxifloxacin, and also lower than vancomycin. 6 These results were consistent with the report from Canada. 4 Nemonoxacin was not so active against E. faecium in vitro. Vancomycin-susceptible Enterococcus isolates were more sensitive to nemonoxacin than vancomycin-resistant strains (Table 1) . 5 Generally, nemonoxacin is not as active for gramnegative bacterial isolates as for gram-positive cocci. Its in vitro activity against Enterobacteriaceae isolates was similar or slightly inferior to the fluoroquinolones tested. 4, 6 Nemonoxacin showed high MIC (MIC 90 .32 mg/L) and low susceptibility to ertapenem-nonsusceptible Enterobacteriaceae. 9, 10 As for the nonfermenters -such as Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii -nemonoxacin generally showed similar activity as other fluoroquinolone comparators. 4, 6 It was reported that nemonoxacin (MIC 90 0.25 mg/L) had 1-to 2-fold lower MIC against Helicobacter pylori than ciprofloxacin, levofloxacin, and moxifloxacin. 11 In a research study from Taiwan, the activity of quinolones against clinical isolates of Clostridium difficile indicated that nemonoxacin was better than moxifloxacin, gemifloxacin, levofloxacin, and ciprofloxacin. 12, 13 The antimicrobial activity of nemonoxacin against other anaerobes was not reported yet. In the testing of clinical isolates of more than 20 Nocardia species, nemonoxacin showed the lowest MIC 90 values (0.5-8 mg/L) among the tested quinolones. 14, 15 Nemonoxacin was less active against Mycobacterium tuberculosis than other quinolones, according to the study from Taiwan. 16 
Resistance induction
Three unrelated clinical isolates of S. pneumoniae were exposed to nemonoxacin to assess the potential of S. pneumoniae to develop resistance to nemonoxacin and to characterize the mutations in topoisomerase II and topoisomerase IV (target genes of fluoroquinolones) associated with nemonoxacin resistance. The MICs of nemonoxacin increased 2-to 8-fold over three cycles of selection (initial MIC 0.03-0.06 mg/L versus final MIC 0.06-0.5 mg/L). Importantly, no highly resistant isolates were induced. In contrast, the MIC of ciprofloxacin had a 64-to 128-fold increase over three selection cycles (initial MIC 0.5 mg/L versus final MIC 32-64 mg/L) and yielded highly resistant isolates. The final MICs were: 0.5-1 mg/L for nemonoxacin; 4 mg/L for moxifloxacin; 4-8 mg/L for gatifloxacin; and 16 mg/L for levofloxacin. 17 After exposure to nemonoxacin, the identified mutations included Ser82Tyr in gyrA, Ser494Thr in gyrB, and Pro454Ser in parE. Nemonoxacin has a low propensity for selecting resistant pathogens compared to other fluoroquinolones, because the bacteria become resistant to nemonoxacin only when three different mutations occur in their quinolone resistance-determining region of the relevant genes. 17 
In vivo antibacterial efficacy
The in vivo efficacy of nemonoxacin was evaluated in mouse models of systemic and local (pulmonary and ascending urinary tract) infections using levofloxacin as a comparator. 18 Used in the infection models were: MSSA (one strain); MRSA (one strain); levofloxacin-and methicillin-resistant S. capitis (one strain); penicillin-intermediate S. pneumoniae (PISP, one strain); penicillin-resistant S. pneumoniae (PRSP, two strains); vancomycin-resistant Enterococcus (VRE, two strains); and Escherichia coli (three strains) isolates. In a systemic infection model, nemonoxacin demonstrated higher therapeutic efficacy against MSSA, MRSA, methicillinresistant S. capitis, PISP, PRSP, and VRE infections with lower effective dose (ED) 50 and MIC values than levofloxacin (P,0.01). 18 Nemonoxacin also exhibited potent activity against E. coli, but the efficacy was lower than that of levofloxacin (P,0.01) ( Table 2) . 18 Another study evaluated the in vivo activity of nemonoxacin in acute murine systemic infections induced by S. aureus, S. pneumoniae, E. coli, ciprofloxacin-resistant S. pneumoniae, and ciprofloxacin-resistant MRSA in comparison with 18 Another study reported the efficacy of nemonoxacin and moxifloxacin in a mouse S. pneumoniae pulmonary infection model and found nemonoxacin more effective than moxifloxacin in reducing S. pneumoniae colonies and protecting mice from death. 20 In the ascending urinary tract infection model, nemonoxacin and levofloxacin showed therapeutic efficacy associated with significantly decreased kidney colony counts in comparison with control group, even though the efficacy of nemonoxacin was lower than that of levofloxacin, based on log CFU/g values of 4.60 versus 3.47 at the 4 mg/kg dose level (P,0.05).
18

Clinical studies Phase i: PK
The PK profile and tolerability of nemonoxacin were investigated in the USA (25, 50, 100, 125, 250, 500, 1,000, and 1,500 mg single dose), 21 the People's Republic of China (125, 250, 500, 750, and 1,000 mg single dose and multiple doses for 10 days), 22, 23 and Taiwan (75, 250, 500, 750, and 1,000 mg once a day for 10 days) (Tables 3 and 4) . 24 In the single-dose trials in healthy volunteers, C max of nemonoxacin was dose proportional over the dose range from 500-1,500 mg. 21, 23 Nemonoxacin rapidly reached its C max within 1-2 hours after a single oral administration (dose range of 25, 50, 125, 250, 500, 750, 1,000, and 1,500 mg) in the fasting state. [21] [22] [23] [24] Following a single dose of 500 mg, the average C max was 3.41-5.91 mg/L (Table 3) . 21, 23 The mean plasma protein binding of nemonoxacin was approximately 16%, which was lower than that of the existing fluoroquinolones, indicating its higher percentage of tissue penetration and lower potential for protein binding-based drug-drug interactions. 21, 23 The apparent V z/F of nemonoxacin (3.81-4.25 L/kg after a single dose of 500 mg) exceeded the total body volume in the study population, suggesting an extensive tissue distribution pattern, which was similar to the existing fluoroquinolones. 21, 23 Nemonoxacin had a long elimination half-life of 10-15 hours, corresponding to the increased doses. [21] [22] [23] [24] Approximately 60%-75% of the administered dose 
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Nemonoxacin in clinical development was excreted in unchanged form via the kidneys over 24-72 hours. [21] [22] [23] The average renal clearance was 140 mL/h/kg in Chinese volunteers, following a single dose of 500 mg 23 and 68 mL/h/kg in the multiracial group after an administration of the same dose. 21 Food had a significant effect on the rate and extent of nemonoxacin absorption (P,0.001), increasing the time to reach C max from 1.14-3.64 hours and reducing C max and area under concentration-time curve (AUC) by 34% and 18%, respectively. Sex effect was not found on the PK parameters of nemonoxacin. The excretion rates in the fed state were 20% lower than those in the fasting state. 23 The multiple-dose PK data suggested little drug accumulation in healthy subjects, evidenced by the plasma concentration which was similar on day 1 and day 10 after administration. 23, 24 The theoretical accumulation ratios (mean ± standard deviation) of the C max and AUC 0-24 were comparable on day 1 and day 10 (1.21±0.06 and 1.11±0.08, respectively). A steady state was reached after 3 days. The mean T 1/2 of nemonoxacin was calculated as 19.65 hours in steady state following multiple doses (Table 4) . When administered at a dose of $500 mg, the plasma concentration of free nemonoxacin maintained above 0.5 mg/L for the full 24-hour dosing interval, which was higher than the MIC 90 values for a wide spectrum of gram-positive pathogens. 24 In preclinical studies, it has been found that nemonoxacin neither induces nor inhibits human hepatic cytochrome P450 3A4 (CYP3A4) activity. 25 Metabolism studies completed to date indicate that no metabolite or a minor metabolite (,5%) of nemonoxacin was formed. 25 
PK/PD profile
Generally, in the PK/PD studies of fluoroquinolones against S. pneumonia, AUC/MIC 90 ratio $25 to approximately 63 or C max / MIC 90 ratio of $8 to approximately 10 is required to predict clinical and microbiological success and to limit the development of bacterial resistance. 26 The MIC 90 of nemonoxacin for S. pneumoniae and S. aureus isolates was #0.125 mg/L. 4 Following administration of 500 mg nemonoxacin, the free AUC/MIC 90 ratio and free C max /MIC ratio were greater than 227 and 24, respectively. 
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Qin and Huang However, a study using an in vitro S. pneumoniae infection model (two-compartment model without absorption delay) indicated a dual-killing pattern of nemonoxacin. It is mainly concentration-dependent when the MIC is low. The better PK/ PD index should be the area under the concentration-time curve for the free, unbound fraction of the drug divided by the MIC (fAUC 0-24 /MIC). When the MIC is high, the time dependency is important. The valid PK/PD index should be the cumulative percentage of a 24-hour period during which the drug concentration exceeds the MIC under steady-state PK conditions (%fT.MIC). 27 
Tolerability
The Phase I studies of oral nemonoxacin with healthy volunteers showed good tolerance and safety. In the singledose study, nemonoxacin was well tolerated up to the maximum dose of 1,500 mg. The most frequent adverse events (AE) were contact dermatitis (12%), pruritus (12%), and erythema (10%). 21 No QT interval prolongation, glucose homeostasis dysregulation, or hepatotoxicity was noted. 21, 23 In the multiple-dose study, the most common AEs were decreased WBC (29.2%), rash (25%), increased alanine aminotransferase (20.8%), nausea (16.7%), and elevated aspartate aminotransferase (16.7%). 23 None of the corrected QT values were more than 500 ms, nor was the corrected QT values difference more than 60 ms -except in one subject from the 750 mg multiple-dose study. 23 
Phase ii clinical trials
Most CAP pathogens, including S. pneumoniae, H. influenzae, K. pneumoniae, and atypical pathogens 28, 29 were proved sensitive to nemonoxacin in the previous preclinical studies as mentioned in this review.
A randomized, double-blind, multicenter Phase II study compared the efficacy and safety of nemonoxacin (500 mg or 750 mg once daily for 7 days) with levofloxacin (500 mg once daily for 7 days) in 265 adult patients with mild-to-moderate CAP. 30 There were 86 patients in the 500 mg nemonoxacin group, 89 in the 750 mg nemonoxacin group, and 90 in the 500 mg levofloxacin group. The primary endpoint was clinical cure rate at the test-of-cure visit. The bacteriological success rate at the test-of-cure visit was assessed in subjects with a baseline pathogen.
The clinical cure rate for 750 mg nemonoxacin, 500 mg nemonoxacin, and 500 mg levofloxacin was 89.9%, 87.0%, and 91.1%, respectively, in the evaluable intent-to-treat (ITT) population; 91.7%, 87.7%, and 90.3%, respectively, in the evaluable per-protocol (PP) population. The 95% confidence interval for the efficacy difference between 750 mg nemonoxacin and 500 mg levofloxacin was −10.4% to 7.9% in the evaluable ITT population and −8.0% to 10.8% in the evaluable PP population. These results indicate that nemonoxacin 750 mg is noninferior to levofloxacin 500 mg. Similarly, noninferiority was demonstrated between nemonoxacin 500 mg and levofloxacin at the same dose level with the 95% confidence interval of −13.9% to 5.7% in the evaluable ITT population and −12.8% to 7.6% in the evaluable PP population.
Overall bacteriological success rate was high for all treatment groups in the bacteriologically evaluable ITT population: 90.2% in the 750 mg nemonoxacin group; 84.8% in the 500 mg nemonoxacin group; and 92.0% in levofloxacin group. The bacteriological success rate for S. pneumoniae was 100% (5/5) in the 750 mg nemonoxacin group, 75% (3/4) in the 500 mg nemonoxacin group, and 100% (5/5) in the 500 mg levofloxacin group. For H. influenzae, the rate was 83% (5/6), 100% (4/4) and 100% (7/7), respectively. The most common atypical pathogen identified serologically was Mycoplasma pneumoniae. The bacteriological success rate was 89.7% (26/29) in 750 mg nemonoxacin group, 80.6% (25/31) in 500 mg nemonoxacin group, and 93.9% (31/33) in levofloxacin group. For C. pneumoniae, the rate was 100% (8/8), 100% (8/8), and 85.7% (6/7) in the three groups, respectively. The bacteriological success rate was 100% for L. pneumophila in all the three groups. For baseline pathogens, the nemonoxacin MIC range was 0.06 to 0.12 mg/L for S. pneumoniae (n=14), which is much lower than the MIC range of levofloxacin (0.5-1 mg/L). The MIC range of nemonoxacin for S. aureus (n=4) was also lower than that of levofloxacin (0.03-0.06 mg/L versus 0.12-0.5 mg/L).
All the three treatments were well-tolerated without reports of drug-related serious AE. No clinically significant difference in drug-related AEs was noted among the three groups. The common AEs in nemonoxacin group occurred in the gastrointestinal (17.4% in 750 mg nemonoxacin group, 11.2% in 500 mg nemonoxacin group, and 8.9% in levofloxacin group) and nervous system (9.3% in 750 mg nemonoxacin group, 6.7% in 500 mg nemonoxacin group, and 4.4% in levofloxacin group), including diarrhea and dizziness. Nevertheless, no difference was found across the treatment groups in the incidence of drug related treatment emergent AEs (31.4% in 750 mg nemonoxacin group, 30.3% in 500 mg nemonoxacin group, and 30.0% in levofloxacin group) (Table 5 ). Nemonoxacin demonstrated a consistently favorable safety profile, as observed in the previous evaluations. In summary, nemonoxacin 500 mg or 750 mg once daily is as effective and well-tolerated as levofloxacin 
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Nemonoxacin in clinical development 500 mg once daily over a 7-day course for the treatment of adults with CAP. 30 In previous in vitro and animal infection models, nemonoxacin showed good activity against MSSA and MRSA. Open-label, noncomparative Phase II trials in patients with mild-to-moderate diabetic foot infection were conducted in US, South Africa, Thailand, and Taiwan. Patients were treated with nemonoxacin 750 mg once daily for 1 or 2 weeks. Four of the 40 enrolled patients were MRSA-infected, including one patient with quinolone-resistant MRSA, who were successfully treated based on clinical evaluation (http://www. taigenbiotech.com/NewsDetail). Further clinical studies are warranted, based on this promising result. 31 Five additional Phase II clinical trials on nemonoxacin are registered on the Internet database (clinicaltrials.gov). Three Phase II oral nemonoxacin studies on pneumonia had been completed, and one Phase II trial of intravenous infusion on pneumonia is still recruiting. The remaining one of oral nemonoxacin on diabetic foot infections was remarked with "completed," but no reports had been published.
Conclusion
Nemonoxacin, a nonfluorinated quinolone, has broadspectrum antibacterial activity covering most gram-positive cocci, atypical pathogens, and most gram-negative bacteria. It is especially more active than the commonly used fluoroquinolones against some typical antibiotic-resistant grampositive cocci, such as PRSP and MRSA.
Nemonoxacin demonstrated excellent efficacy in fighting systemic and local infections in murine models. The sound PK profile of nemonoxacin is characteristic of short time to reach C max , long T 1/2 , low plasma protein-binding rate, and large apparent V z/F similar to the fluoroquinolones. Its superior PK/PD features can predict sound clinical efficacy, which is reflected in clinical trial in CAP patients. Oral administration of nemonoxacin at a dose of 500 mg and 750 mg once daily for 7 days is proved as effective and safe as levofloxacin 500 mg once a day in the patients with CAP. The upcoming results from the ongoing clinical trials will further prove the clinical value of oral and intravenous nemonoxacin in treating CAP and other relevant infections. Table 5 Number and frequency of subjects with drug-related TeAe (.2%) in the phase ii clinical trial of nemonoxacin for treating community-acquired pneumonia 
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